Merck & Co (MRK) DIvidends Date & History

Key Takeaways

• Quarterly dividend of $0.85 per share, or $3.40 annually, with a current dividend yield of roughly 2.3%.
• 14 consecutive years of dividend growth, with an average annual increase near 5.75% over the past five years.
• Dividend is well covered by cash flow — the cash-flow payout ratio is around 30% — even though trailing earnings appear temporarily distorted.
• A modest but dependable yield that is better suited to dividend-growth and income-oriented investors than to high-yield seekers.
• Recent ex-dividend date of September 15, 2026, with a payment date of October 7, 2026.

Dividend Overview

Merck & Co., Inc. (MRK) is a global pharmaceutical leader best known for its oncology franchise, led by Keytruda, along with vaccines such as Gardasil and a substantial animal-health business. The company pays a quarterly cash dividend of $0.85 per share, which annualizes to $3.40 and translates to a dividend yield of approximately 2.3% at recent prices. Merck is best described as a dividend-growth stock rather than a high-yield stock: its payout is reliable and steadily rising, but the yield is modest relative to some of its large-cap pharmaceutical peers. Payments are made quarterly, typically in January, April, July, and October, giving investors a predictable income stream. For shareholders focused on long-term, compounding income growth rather than maximum current yield, Merck's dividend profile represents a balanced middle ground within the healthcare sector.

Dividend History and Growth

Merck has a long-standing commitment to returning capital to shareholders and has paid a dividend consistently for decades. The company has now increased its payout for 14 consecutive years, qualifying it as a developing dividend-growth story rather than an established "Dividend Aristocrat" with 25-plus years of increases. The most recent increase came on November 18, 2025, when the quarterly dividend was raised by $0.04, from $0.81 to $0.85 per share — a year-over-year increase of about 4.94%. Over the past five years, Merck's dividend has grown at an average annualized rate of approximately 5.75%, and over the past decade the pace has been in the mid-single digits. This steady, incremental approach reflects management's preference for consistent, sustainable increases tied to the company's long-term earnings and cash-flow growth, rather than large, aggressive hikes.

Dividend Sustainability and Payout Ratio

Merck's dividend appears sustainable when viewed through the lens of cash flow. The company pays out roughly 30% of its operating cash flow as dividends — a conservative level that leaves ample room for reinvestment in research and development. The earnings-based payout ratio tells a more complicated story: trailing figures show a ratio well above 100% because Merck's reported earnings per share (EPS) were temporarily depressed by a large, one-time charge related to a Keytruda patent litigation settlement recorded in late 2025. Excluding that non-cash, non-recurring item, analysts' forward estimates imply a payout ratio closer to 35%, which is comfortably within Merck's historical norms. The company also carries a solid balance sheet, with a debt-to-equity ratio of about 0.80, and generates consistent free cash flow. Taken together, these factors suggest the dividend is well protected and that the elevated trailing payout ratio is an accounting distortion rather than a sign of financial strain.

Dividend Compared to Industry Peers

Within the large-cap pharmaceutical space, Merck's yield sits in the middle of the pack. Its roughly 2.3% yield is higher than fast-growing names such as Eli Lilly (LLY), whose yield is well below 1%, but lower than income-heavy rivals such as Pfizer (PFE) and Bristol Myers Squibb (BMY), which often carry yields above 5%. It is also somewhat below peers like AbbVie (ABBV) and Johnson & Johnson (JNJ), which generally yield around 3% or more. In exchange for a lower current yield, Merck offers a comparatively faster dividend-growth trajectory and a strong growth pipeline anchored by Keytruda and its vaccine portfolio. For investors weighing income today against income tomorrow, Merck represents a balance of modest yield with meaningful, consistent growth.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can help identify dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening. Whether you are building a dividend-income watchlist or searching for the next growth catalyst, the AI Screener streamlines the research process with data-driven, objective signals.

Is This Stock Attractive for Dividend Investors?

Merck may appeal primarily to dividend-growth investors and long-term, total-return-oriented investors rather than those seeking the highest current income. With a yield near 2.3% and a 14-year track record of steady increases averaging around 5.75% annually, the company offers a growing income stream backed by robust cash-flow coverage and a diversified pharmaceutical portfolio. Conservative, income-focused investors may appreciate the predictability of quarterly payments and the modest cash-flow payout ratio, while more aggressive yield seekers may find better current income elsewhere in the sector. Merck's dividend is not immune to pipeline and patent-cycle risks, and its recent earnings distortion underscores the importance of evaluating cash flow rather than headline earnings. On balance, the stock fits investors who value dependable, compounding dividend growth and are comfortable holding through pharmaceutical-sector cycles. As with any investment, individual goals, risk tolerance, and time horizon should guide the decision.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations